RxDoctor Payments Data

Amanda Wilson, PA

Physician Assistant · Cheektowaga, NYNPI 1467826776

Payments from drug & device makers

$13,084in general payments, 2019–2025

Across 668 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • AbbVie$947
  • Esperion Therapeutics, Inc.$803
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$13,01899%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,084 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$15,621
Medicare patients
90
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$52,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$39,231
EliquisApixaban26$34,651
JardianceEmpagliflozin13$20,041
MounjaroTirzepatide15$15,654
Breo ElliptaFluticasone/Vilanterol15$7,240
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$4,604
Levothyroxine Sodium153$3,412
Atorvastatin Calcium195$3,061
Rosuvastatin Calcium150$2,478
Lisinopril139$1,921
Albuterol Sulfate HfaAlbuterol Sulfate54$1,827
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,813
SynthroidLevothyroxine Sodium22$1,604
Omeprazole88$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,598$52,75236 claims
GSKTrelegy Ellipta, Breo Ellipta$1,034$46,47158 claims
PfizerEliquis$396$34,65126 claims
Boehringer IngelheimJardiance$465$20,04113 claims
Lilly USA, LLCMounjaro$1,236$15,65415 claims
AbbVieSynthroid$947$1,60422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Cheektowaga

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →